Department of Epidemiology and Biostatistics, University of California San Francisco, UCSF Box 0560, 550 16th St. 2nd Floor, San Francisco, CA, 94158, USA.
Department of Urology, University of California San Francisco, San Francisco, CA, USA.
BMC Cancer. 2019 Mar 11;19(1):218. doi: 10.1186/s12885-019-5427-5.
Over 1.3 million people live with colorectal cancer in the United States. Physical activity is associated with lower risk of colorectal cancer recurrence and mortality. Interventions are needed to increase physical activity in colorectal cancer survivors.
We conducted a 2-arm non-blinded pilot randomized controlled trial at the University of California, San Francisco among 42 individuals who had completed curative-intent treatment for colorectal cancer to determine the feasibility and acceptability of a 12-week (84 days) physical activity intervention using a Fitbit Flex™ and daily text messages. Participants were randomized 1:1 to receive the intervention with print educational materials or print educational materials alone. We explored the impact of the intervention versus usual care on physical activity using ActiGraph GT3X+ accelerometers pre-/post-intervention.
We screened 406 individuals and randomized 42 to intervention (n = 21) or control (n = 21) groups. During the 12-week study, the intervention arm wore their Fitbits a median of 74 days [88% of days in study period, interquartile range: 23-83 days] and responded to a median of 34 (out of 46) text messages that asked for a reply (interquartile range: 13-38 text messages). Among the 16 intervention participants who completed the feedback survey, the majority (88%) reported that the intervention motivated them to exercise and that they were satisfied with their experience. No statistically significant difference in change in moderate-to-vigorous physical activity was found from baseline to 12 weeks between arms.
A 12-week physical activity intervention with a Fitbit and text messages was feasible and acceptable among colorectal cancer patients after curative treatment. Larger studies are needed to determine whether the intervention increases physical activity.
Clinicaltrials.gov Identifier NCT02966054 . Registered 17 November 2016, retrospectively registered.
在美国,有超过 130 万人患有结直肠癌。身体活动与结直肠癌复发和死亡风险降低有关。需要采取干预措施来增加结直肠癌幸存者的身体活动量。
我们在美国加利福尼亚大学旧金山分校进行了一项为期 12 周(84 天)的 2 臂非盲试点随机对照试验,共有 42 名已完成根治性治疗的结直肠癌患者参与,以确定使用 Fitbit Flex™和每日短信进行为期 12 周的身体活动干预的可行性和可接受性。参与者以 1:1 的比例随机分为干预组(接受干预+印刷教育材料)和对照组(仅接受印刷教育材料)。我们使用 ActiGraph GT3X+加速度计在干预前/后评估干预对身体活动的影响。
我们共筛选了 406 名患者,并将 42 名患者随机分配到干预组(n=21)或对照组(n=21)。在 12 周的研究期间,干预组佩戴 Fitbit 的中位数天数为 74 天[研究期间的 88%天数,四分位距:23-83 天],回复了中位数 34 条(共 46 条)短信(四分位距:13-38 条短信)。在完成反馈调查的 16 名干预参与者中,大多数(88%)表示干预激励他们锻炼,并且对他们的体验感到满意。与基线相比,两组在 12 周时的中等至剧烈身体活动量的变化没有统计学上的显著差异。
在接受根治性治疗后,结直肠癌患者使用 Fitbit 和短信进行为期 12 周的身体活动干预是可行和可接受的。需要更大规模的研究来确定该干预是否能增加身体活动量。
Clinicaltrials.gov 标识符 NCT02966054。于 2016 年 11 月 17 日注册,回顾性注册。